

Resource Summary Report

Generated by [RRID](#) on Sep 7, 2026

HEY

RRID:CVCL_0297

Type: Cell Line

Proper Citation

RRID:CVCL_0297

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0297

Proper Citation: RRID:CVCL_0297

Description: Cell line HEY is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: High grade ovarian serous adenocarcinoma

Defining Citation: [PMID:3731068](#), [PMID:4016745](#), [PMID:12960427](#), [PMID:19926575](#), [PMID:20204287](#), [PMID:22710073](#), [PMID:23415752](#), [PMID:24023729](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30485824](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HEY

Synonyms: Hey

Cross References: BTO:BTO_0002590, EFO:EFO_0006580, MCCL:MCC:0000188, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:866, BioSample:SAMN03473280, cancercellines:CVCL_0297, Cell_Model_Passport:SIDM00968, ChEMBL-Cells:ChEMBL3308082, ChEMBL-Targets:ChEMBL613869, CLS:305017, Cosmic:1102812, Cosmic:1524358, Cosmic-CLP:1479988, DepMap:ACH-002140, EGA:EGAS00001000610,

EGA:EGAS00001000978, GDSC:1479988, GEO:GSM659377, GEO:GSM1340581, GEO:GSM1669880, IARC_TP53:28489, PharmacDB:HEY_541_2019, PRIDE:PXD030304, PubChem_Cell_line:CVCL_0297, Wikidata:Q54883211

ID: CVCL_0297

Hierarchy: cvcl_4995

Record Creation Time: 20220427T220340+0000

Record Last Update: 20260905T180301+0000

Ratings and Alerts

No rating or validation information has been found for HEY.

No alerts have been found for HEY.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 23 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#).

Li Y, et al. (2026) Disruption of the SNRPF-DDX24-E2F4 Feedback Loop Uncouples Splicing and Transcriptional Regulation to Suppress Ovarian Cancer Progression. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e23374.

Huang B, et al. (2026) The long noncoding RNA AC093895.1 promotes ovarian cancer formation and metastasis through a positive feedback network dependent on the transcription factor SOX4. Cell death & disease, 17(1), 202.

Meng H, et al. (2026) Multiomics profiling and experiments in preclinical models revealed RAD51-IN-1 as a synergistic potentiator of anlotinib sensitivity. Science advances, 12(16), eaeb0855.

Zhang F, et al. (2026) The central precocious puberty-associated gene MKRN3 is a tumor suppressor regulating CSDE1 ubiquitination in ovarian cancer. Oncogenesis, 15(1).

Liu W, et al. (2025) Serum metabolic fingerprints encode functional biomarkers for ovarian cancer diagnosis: a large-scale cohort study. EBioMedicine, 115, 105706.

Ding C, et al. (2025) A Tumor-homing nanoplatform for the co-delivery of triptolide and siRNA-A4B2 conspicuously overcomes peritoneum metastasis of ovarian cancer. Cellular oncology (Dordrecht, Netherlands), 48(6), 1741.

Kasama H, et al. (2025) Laeverin is Cell-Surface Target for Liquid-Phase Metastasizing Cancer Cells. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 12(47), e11349.

Li DX, et al. (2025) COPB2 facilitates EDEM3-mediated mannose trimming to sustain ER homeostasis in ovarian cancer. *Cellular oncology* (Dordrecht, Netherlands).

Che X, et al. (2025) TRIM4 modulates the ubiquitin-mediated degradation of hnRNPD and weakens sensitivity to CDK4/6 inhibitor in ovarian cancer. *Frontiers of medicine*, 19(1), 121.

Guo Z, et al. (2025) Differential regulation of FADS2 by EZH2 reveals a metabolic vulnerability in ovarian cancer treatment. *EBioMedicine*, 119, 105879.

Wang W, et al. (2025) CD38 contributes to tumor progression and tumor microenvironment reshaping in epithelial ovarian cancer. *Translational oncology*, 57, 102414.

Furutake Y, et al. (2024) YAP1 Suppression by ZDHHC7 Is Associated with Ferroptosis Resistance and Poor Prognosis in Ovarian Clear Cell Carcinoma. *Molecular cancer therapeutics*, 23(11), 1652.

Wen J, et al. (2023) TUBA1A licenses APC/C-mediated mitotic progression to drive glioblastoma growth by inhibiting PLK3. *FEBS letters*, 597(24), 3072.

Yang S, et al. (2023) Function of m5C RNA methyltransferase NOP2 in high-grade serous ovarian cancer. *Cancer biology & therapy*, 24(1), 2263921.

Young KM, et al. (2023) Correlating mechanical and gene expression data on the single cell level to investigate metastatic phenotypes. *iScience*, 26(4), 106393.

Yang J, et al. (2022) Chondroitin sulfate proteoglycan 4, a targetable oncoantigen that promotes ovarian cancer growth, invasion, cisplatin resistance and spheroid formation. *Translational oncology*, 16, 101318.

Kitami K, et al. (2022) Peritoneal restoration by repurposing vitamin D inhibits ovarian cancer dissemination via blockade of the TGF- β 1/thrombospondin-1 axis. *Matrix biology : journal of the International Society for Matrix Biology*, 109, 70.

Braal CL, et al. (2021) Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences. *Drugs*, 81(3), 317.

Stalin J, et al. (2020) Therapeutic targeting of soluble CD146/MCAM with the M2J-1 monoclonal antibody prevents metastasis development and procoagulant activity in CD146-positive invasive tumors. *International journal of cancer*, 147(6), 1666.

Jung M, et al. (2020) ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancer. *International journal of cancer*, 147(8), 2225.